Calibration and validation of the rabbit model of electrolytic‐mediated arterial thrombosis against the standard‐of‐care anticoagulant apixaban

Calibration and validation of the rabbit model of electrolytic‐mediated arterial thrombosis against the standard‐of‐care anticoagulant apixaban

Abstract Apixaban is a factor Xa (FXa) inhibitor and standard‐of‐care anticoagulant with FXa Ki and plasma protein binding (free fraction) averages 0.08 nM and 0.13 in humans and 0.16 nM and 0.37 in rabbits, respectively. Apixaban at the approved dose of 5 mg BID achieved maximum and minimum plasma...

Full description

Bibliographic Details
Main Authors:	Pancras C. Wong, Earl Crain
Format:	Article
Language:	English
Published:	Wiley 2022-06-01
Series:	Pharmacology Research & Perspectives
Subjects:	anticoagulant blood coagulation factor Xa inhibitor thrombosis translation
Online Access:	https://doi.org/10.1002/prp2.963

Similar Items

Anticoagulant SERPINs: Endogenous Regulators of Hemostasis and Thrombosis
by: Steven P. Grover, et al.
Published: (2022-05-01)

Usefullness of Heparin Calibrated Anti-Xa Activity to Assess Anticoagulant Activity of Apixaban and Rivaroxaban in Emergency Patients Scheduled for Acute Interventions
by: Nada Riahi, et al.
Published: (2023-10-01)

ERA OF NEW ANTICOAGULANTS IN THE TREATMENT OF NON-VALVULAR ATRIAL FIBRILLATION: PROSPECTS AND CHALLENGES
by: Z. M. Safiullina, et al.
Published: (2015-09-01)

Viscoelastometry for detecting oral anticoagulants
by: Philipp Groene, et al.
Published: (2021-03-01)

Pharmacokinetics and Biologic Activity of Apixaban in Healthy Dogs
by: Noelle D. Herrera, et al.
Published: (2021-07-01)

Venous thrombosis recurrence risk according to warfarin versus direct oral anticoagulants for the secondary prevention of venous thrombosis
by: Neil A. Zakai, et al.
Published: (2021-08-01)

Electrochemical Monitoring in Anticoagulation Therapy
by: Ashwin K. V. Mruthunjaya, et al.
Published: (2024-03-01)

Direct oral anticoagulants compared to low‐molecular‐weight heparin for the treatment of cancer‐associated thrombosis: Updated systematic review and meta‐analysis of randomized controlled trials
by: Florian Moik, et al.
Published: (2020-05-01)

Improved efficacy/safety profile of factor XIa inhibitor BMS‐724296 versus factor Xa inhibitor apixaban and thrombin inhibitor dabigatran in cynomolgus monkeys
by: Pancras C. Wong, et al.
Published: (2021-05-01)

Bleeding issues in women prescribed anticoagulation
by: V. Speed, et al.
Published: (2021-12-01)

Measurement of Anticoagulation in Patients on Dabigatran, Rivaroxaban, and Apixaban Therapy by Novel Automated Thrombelastography
by: Ramin Artang, et al.
Published: (2021-10-01)

The Relative Efficacy of Chemically Diverse Small-Molecule Enzyme-Inhibitors Against Anticoagulant Activities of African Spitting Cobra (Naja Species) Venoms
by: Abhinandan Chowdhury, et al.
Published: (2021-10-01)

Apixaban Reduces Hospitalizations in Patients With Venous Thromboembolism: An Analysis of the Apixaban for the Initial Management of Pulmonary Embolism and Deep‐Vein Thrombosis as First‐Line Therapy (AMPLIFY) Trial
by: Xianchen Liu, et al.
Published: (2015-12-01)

Anticoagulant treatment: the end of the old agents?
by: Lukas Graf, et al.
Published: (2012-09-01)

Evaluation of the effect of apixaban using a viscoelastic coagulation assay with Russell’s viper venom reagent
by: Kaoru Suzuki, et al.
Published: (2021-05-01)

Direct Oral Anticoagulant Use: A Practical Guide to Common Clinical Challenges
by: Ashley Chen, et al.
Published: (2020-07-01)

Modified thromboelastometric tests provide improved sensitivity and specificity to direct oral anticoagulants compared to standard thromboelastometric tests in-vitro
by: Philipp Groene, et al.
Published: (2022-07-01)

Evaluating efficacy and safety of oral anticoagulation in adult patients with atrial fibrillation and cancer: A systemic review and meta-analysis
by: L.A. Ciuffini, et al.
Published: (2023-08-01)

ORAL ANTICOAGULANTS IN THE TREATMENT OF VENOUS THROMBOEMBOLIC COMPLICATIONS: FOCUS ON APIXABAN
by: M. Yu. Gilyarov, et al.
Published: (2017-12-01)

Anticoagulation in the Elderly
by: Helia Robert-Ebadi, et al.
Published: (2010-12-01)

Efficacy and safety of Apixaban for the prevention of thrombosis in arteriovenous grafts
by: Arash Hedayat, et al.
Published: (2024-01-01)

Bleeding complications in patients with gastrointestinal cancer and atrial fibrillation treated with oral anticoagulants
by: Anne Gulbech Ording, et al.
Published: (2021-07-01)

EXTENDED THERAPY OF VENOUS THROMBOSIS BY ORAL ANTICOAGULANTS: FOCUS AT SAFETY
by: I. V. SCHASTLIVTSEV, et al.
Published: (2016-12-01)

The Potential Role of Coagulation Factor Xa in the Pathophysiology of COVID-19: A Role for Anticoagulants as Multimodal Therapeutic Agents
by: Galit H. Frydman, et al.
Published: (2020-10-01)

Comparative analysis of enoxaparin versus rivaroxaban in the treatment of cancer associated venous thromboembolism: experience from a tertiary care cancer centre
by: Anadil Faqah, et al.
Published: (2020-05-01)

On-treatment follow-up in real-world studies of direct oral anticoagulants in atrial fibrillation: Association with treatment effects
by: David Hutto, et al.
Published: (2022-06-01)

Dental extractions on direct oral anticoagulants vs. warfarin: The DENTST study
by: Yvonne Brennan, et al.
Published: (2020-02-01)

Self‐reported therapy adherence and predictors for nonadherence in patients who switched from vitamin K antagonists to direct oral anticoagulants
by: Myrthe M. A. Toorop, et al.
Published: (2020-05-01)

Transcatheter Heart Valve Thrombosis in a Patient With Polycythemia Vera Despite Apixaban Therapy for Atrial Fibrillation
by: Gauranga Mahalwar, MD, et al.
Published: (2021-02-01)

Direct Oral Anticoagulants in Dental Patients Including the Frail Elderly Population
by: Hui Yin Lim, et al.
Published: (2016-03-01)

Direct oral anticoagulant: Review article
by: Abdulrahman Nasiri, et al.
Published: (2022-01-01)

Thrombosis Prevention without Anticoagulation
by: Alvin H. Schmaier
Published: (2014-05-01)

Accuracy of a Single, Heparin-Calibrated Anti-Xa Assay for the Measurement of Rivaroxaban, Apixaban, and Edoxaban Drug Concentrations: A Prospective Cross-Sectional Study
by: Tamana Meihandoest, et al.
Published: (2022-03-01)

Portal vein thrombosis (PVT): a study of 20 non-cirrhotic cases
by: G Kocher, et al.
Published: (2005-07-01)

The novel anticoagulants: entering a new era
by: Swiss Medical Weekly
Published: (2009-02-01)

Inhibition of thrombin generation 12 hours after intake of direct oral anticoagulants
by: Michael Metze, et al.
Published: (2020-05-01)

Pharmacokinetics and Pharmacodynamics of an Oral Formulation of Apixaban in Horses After Oral and Intravenous Administration
by: Priscila B. S. Serpa, et al.
Published: (2018-12-01)

Etiology of Ischemic Strokes of Patients with Atrial Fibrillation and Therapy with Anticoagulants
by: Jan C. Purrucker, et al.
Published: (2020-09-01)

Point-of-care detection and differentiation of anticoagulant therapy - development of thromboelastometry-guided decision-making support algorithms
by: Simon T. Schäfer, et al.
Published: (2021-09-01)

Comparison of Treatment Result Between Anticoagulation Alone and Catheter-Directed Thrombolysis Plus Anticoagulation in Acute Lower Extremity Deep Vein Thrombosis
by: Young Jin Choi, et al.
Published: (2019-03-01)